{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:51Z","timestamp":1789450491457,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS108686"],"award-info":[{"award-number":["NS108686"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS112540"],"award-info":[{"award-number":["NS112540"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["-NS092093"],"award-info":[{"award-number":["-NS092093"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS086074"],"award-info":[{"award-number":["NS086074"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ASAP\/MJFF","award":["ASAP-000592"],"award-info":[{"award-number":["ASAP-000592"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neuronal dysfunction and degeneration linked to \u03b1-synuclein (\u03b1S) pathology is thought to be responsible for the progressive nature of Parkinson\u2019s disease and related dementia with Lewy bodies. Studies have indicated bidirectional pathological relationships between \u03b1S pathology and tau abnormalities. We recently showed that A53T mutant human \u03b1S (Hu\u03b1S) can cause post-synaptic and cognitive deficits that require microtubule-associated protein tau expression. However, the role of tau in the development of \u03b1S pathology and subsequent neuronal dysfunction has been controversial. Herein, we set out to determine the role of tau in the onset and progression of \u03b1S pathology (\u03b1-synucleinopathy) using a transgenic mouse model of \u03b1-synucleinopathy lacking mouse tau expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Transgenic mice expressing A53T mutant Hu\u03b1S (TgA53T) were crossed with mTau<jats:sup>\u2212\/\u2212<\/jats:sup> mice to generate TgA53T\/mTau<jats:sup>\u2212\/\u2212<\/jats:sup>. To achieve more uniform induction of \u03b1-synucleinopathy in mice, we used intramuscular injections of \u03b1S preformed fibrils (PFF) in non-transgenic (nTg), TgA53T, TgA53T\/mTau<jats:sup>\u2212\/\u2212<\/jats:sup>, and mTau<jats:sup>\u2212\/\u2212<\/jats:sup> mice. Motor behavior was analyzed at 70\u00a0days post inoculation (dpi) of PFF and tissues for biochemical and neuropathological analysis were collected at 40 dpi, 70 dpi, and end stage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Loss of tau expression significantly delayed the onset of motor deficits in the TgA53T model and the progression of \u03b1-synucleinopathy disease, as evidenced by a significant reduction in histopathological and behavioral markers of neurodegeneration and disease, and a significant improvement in survival. In vitro application of PFF to primary mouse hippocampal neurons demonstrated no changes in PFF uptake and processing or pS129 \u03b1S aggregation as a function of tau expression. However, PFF-induced neurotoxicity, including morphological deficits in nTg neurons, was prevented with tau removal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Collectively, our data suggest that tau is likely acting downstream of \u03b1S pathology to affect neuronal homeostasis and survival. This work further supports the investigation of tau in \u03b1-synucleinopathies to identify novel disease-modifying therapeutic strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40035-022-00309-x","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:03:03Z","timestamp":1656633783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Loss of tau expression attenuates neurodegeneration associated with \u03b1-synucleinopathy"],"prefix":"10.1186","volume":"11","author":[{"given":"Scott C.","family":"Vermilyea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Meints","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balvindar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Martell-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Razaul","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5865-9682","authenticated-orcid":false,"given":"Michael K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"309_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"309_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/jnen\/61.5.413","volume":"61","author":"K Del Tredici","year":"2002","unstructured":"Del Tredici K, R\u00fcb U, de Vos RAI, Bohl JRE, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413\u201326.","journal-title":"J Neuropathol Exp Neurol"},{"key":"309_CR3","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1073\/pnas.132197599","volume":"99","author":"MK Lee","year":"2002","unstructured":"Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, et al. Human \u03b1-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53 \u2192 Thr mutation causes neurodegenerative disease with \u03b1-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002;99:8968\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"309_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00401-019-02032-w","volume":"138","author":"B Singh","year":"2019","unstructured":"Singh B, Covelo A, Martell-Mart\u00ednez H, Nanclares C, Sherman MA, Okematti E, et al. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy. Acta Neuropathol. 2019;138(4):551\u201374.","journal-title":"Acta Neuropathol"},{"key":"309_CR5","doi-asserted-by":"publisher","first-page":"9754","DOI":"10.1523\/JNEUROSCI.0344-18.2018","volume":"38","author":"PJ Teravskis","year":"2018","unstructured":"Teravskis PJ, Covelo A, Miller EC, Singh B, Martell-Mart\u00ednez HA, Benneyworth MA, et al. A53T mutant alpha-synuclein induces tau-dependent postsynaptic impairment independently of neurodegenerative changes. J Neurosci. 2018;38:9754\u201367.","journal-title":"J Neurosci"},{"key":"309_CR6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192193","volume":"218","author":"F Bassil","year":"2021","unstructured":"Bassil F, Meymand ES, Brown HJ, Xu H, Cox TO, Pattabhiraman S, et al. \u03b1-Synuclein modulates tau spreading in mouse brains. J Exp Med. 2021;218: e20192193.","journal-title":"J Exp Med"},{"key":"309_CR7","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/j.1460-9568.2011.07660.x","volume":"33","author":"T Haggerty","year":"2011","unstructured":"Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, Masliah E, et al. Hyperphosphorylated Tau in an \u03b1-synuclein-overexpressing transgenic model of Parkinson\u2019s disease: Tauopathy in transgenic mice and PD. Eur J Neurosci. 2011;33:1598\u2013610.","journal-title":"Eur J Neurosci"},{"key":"309_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.mcn.2011.09.002","volume":"49","author":"PJ Khandelwal","year":"2012","unstructured":"Khandelwal PJ, Dumanis SB, Herman AM, Rebeck GW, Moussa CE-H. Wild type and P301L mutant Tau promote neuro-inflammation and \u03b1-Synuclein accumulation in lentiviral gene delivery models. Mol Cell Neurosci. 2012;49:44\u201353.","journal-title":"Mol Cell Neurosci"},{"key":"309_CR9","doi-asserted-by":"publisher","first-page":"e29257","DOI":"10.1371\/journal.pone.0029257","volume":"6","author":"M Morris","year":"2011","unstructured":"Morris M, Koyama A, Masliah E, Mucke L. Tau reduction does not prevent motor deficits in two mouse models of Parkinson\u2019s disease. PLoS One. 2011;6:e29257.","journal-title":"PLoS ONE"},{"key":"309_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-018-0245-9","volume":"13","author":"JE Gerson","year":"2018","unstructured":"Gerson JE, Farmer KM, Henson N, Castillo-Carranza DL, Carretero Murillo M, Sengupta U, et al. Tau oligomers mediate \u03b1-synuclein toxicity and can be targeted by immunotherapy. Mol Neurodegener. 2018;13:13.","journal-title":"Mol Neurodegener"},{"key":"309_CR11","doi-asserted-by":"crossref","unstructured":"Stoyka LE, Mahoney CL, Thrasher DR, Russell DL, Cook AK, Harris AT, et al. Templated \u03b1-synuclein inclusion formation is independent of endogenous tau. eNeuro. 2021;8:ENEURO.0458-20.2021.","DOI":"10.1523\/ENEURO.0458-20.2021"},{"key":"309_CR12","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.1073\/pnas.1321785111","volume":"111","author":"AN Sacino","year":"2014","unstructured":"Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, et al. Intramuscular injection of -synuclein induces CNS \u03b1-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci USA. 2014;111:10732\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"309_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/82868","volume":"4","author":"KL Tucker","year":"2001","unstructured":"Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4:29\u201337.","journal-title":"Nat Neurosci"},{"key":"309_CR14","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1523\/JNEUROSCI.5368-11.2012","volume":"32","author":"E Colla","year":"2012","unstructured":"Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic -synuclein oligomer within endoplasmic reticulum occurs in -synucleinopathy in vivo. J Neurosci. 2012;32:3301\u20135.","journal-title":"J Neurosci"},{"key":"309_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-020-00364-w","volume":"15","author":"MdR Karim","year":"2020","unstructured":"Karim MdR, Liao EE, Kim J, Meints J, Martinez HM, Pletnikova O, et al. \u03b1-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Mol Neurodegener. 2020;15:27.","journal-title":"Mol Neurodegener"},{"key":"309_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1523\/JNEUROSCI.4308-05.2006","volume":"26","author":"LJ Martin","year":"2006","unstructured":"Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, et al. Parkinson\u2019s disease \u03b1-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006;26:41\u201350.","journal-title":"J Neurosci"},{"key":"309_CR17","doi-asserted-by":"publisher","first-page":"13805","DOI":"10.1523\/JNEUROSCI.4218-08.2008","volume":"28","author":"Y Liu","year":"2008","unstructured":"Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci. 2008;28:13805\u201314.","journal-title":"J Neurosci"},{"key":"309_CR18","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley LA, Luk KC, Lee VM-Y. Addition of exogenous \u03b1-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous \u03b1-synuclein to Lewy body and Lewy neurite\u2013like aggregates. Nat Protoc. 2014;9:2135\u201346.","journal-title":"Nat Protoc"},{"key":"309_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0165-0270(96)02211-X","volume":"73","author":"K Matsuura","year":"1997","unstructured":"Matsuura K, Kabuto H, Makino H, Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods. 1997;73:45\u20138.","journal-title":"J Neurosci Methods"},{"key":"309_CR20","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1523\/JNEUROSCI.5367-11.2012","volume":"32","author":"E Colla","year":"2012","unstructured":"Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, et al. Endoplasmic reticulum stress is important for the manifestations of -synucleinopathy in vivo. J Neurosci. 2012;32:3306\u201320.","journal-title":"J Neurosci"},{"key":"309_CR21","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.1523\/JNEUROSCI.1370-04.2004","volume":"24","author":"W Li","year":"2004","unstructured":"Li W. Stabilization of -synuclein protein with aging and familial Parkinson\u2019s disease-linked A53T mutation. J Neurosci. 2004;24:7400\u20139.","journal-title":"J Neurosci"},{"key":"309_CR22","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1073\/pnas.0406976102","volume":"102","author":"W Li","year":"2005","unstructured":"Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, et al. Aggregation promoting C-terminal truncation of -synuclein is a normal cellular process and is enhanced by the familial Parkinson\u2019s disease-linked mutations. Proc Natl Acad Sci U S A. 2005;102:2162\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"309_CR23","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/j.1471-4159.2005.03146.x","volume":"93","author":"W Li","year":"2005","unstructured":"Li W, Lee MK. Antiapoptotic property of human \u03b1-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity: Antiapoptotic property of human \u03b1-synuclein. J Neurochem. 2005;93:1542\u201350.","journal-title":"J Neurochem"},{"key":"309_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00401-018-1886-z","volume":"136","author":"SS Khan","year":"2018","unstructured":"Khan SS, LaCroix M, Boyle G, Sherman MA, Brown JL, Amar F, et al. Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. Acta Neuropathol. 2018;136:589\u2013605.","journal-title":"Acta Neuropathol"},{"key":"309_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-019-01977-2","volume":"138","author":"ZA Sorrentino","year":"2019","unstructured":"Sorrentino ZA, Giasson BI, Chakrabarty P. \u03b1-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathol. 2019;138:1\u201321.","journal-title":"Acta Neuropathol"},{"key":"309_CR26","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1111\/j.1742-4658.2011.08389.x","volume":"278","author":"F Kawakami","year":"2011","unstructured":"Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, Tamura K, et al. Stimulatory effect of \u03b1-synuclein on the tau-phosphorylation by GSK-3\u03b2: \u03b1-Synuclein induced hyperphosphorylation of tau. FEBS J. 2011;278:4895\u2013904.","journal-title":"FEBS J"},{"key":"309_CR27","doi-asserted-by":"publisher","first-page":"e17953","DOI":"10.1371\/journal.pone.0017953","volume":"6","author":"J Wills","year":"2011","unstructured":"Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, Sidhu A. Tauopathic changes in the striatum of A53T \u03b1-synuclein mutant mouse model of Parkinson\u2019s disease. PLoS One. 2011;6:e17953.","journal-title":"PLoS ONE"},{"key":"309_CR28","doi-asserted-by":"publisher","first-page":"8602","DOI":"10.1038\/s41598-017-09239-5","volume":"7","author":"A Krishnankutty","year":"2017","unstructured":"Krishnankutty A, Kimura T, Saito T, Aoyagi K, Asada A, Takahashi SI, et al. In vivo regulation of glycogen synthase kinase 3\u03b2 activity in neurons and brains. Sci Rep. 2017;7:8602.","journal-title":"Sci Rep"},{"key":"309_CR29","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/pnas.1913904117","volume":"117","author":"AL Mahul-Mellier","year":"2020","unstructured":"Mahul-Mellier AL, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, et al. The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020;117:4971\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"309_CR30","doi-asserted-by":"publisher","first-page":"fcaa090","DOI":"10.1093\/braincomms\/fcaa090","volume":"2","author":"T Williams","year":"2020","unstructured":"Williams T, Sorrentino Z, Weinrich M, Giasson BI, Chakrabarty P. Differential cross-seeding properties of tau and \u03b1-synuclein in mouse models of tauopathy and synucleinopathy. Brain Commun. 2020;2:fcaa090.","journal-title":"Brain Commun"},{"key":"309_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.expneurol.2004.01.007","volume":"187","author":"P Kotzbauer","year":"2004","unstructured":"Kotzbauer P. Fibrillization of \u03b1-synuclein and tau in familial Parkinson\u2019s disease caused by the A53T\u202f\u03b1-synuclein mutation. Exp Neurol. 2004;187:279\u201388.","journal-title":"Exp Neurol"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-022-00309-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-022-00309-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-022-00309-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:05:41Z","timestamp":1656633941000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-022-00309-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["309"],"URL":"https:\/\/doi.org\/10.1186\/s40035-022-00309-x","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"27 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols involving mice were in strict adherence to the NIH Animal Care and Guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Minnesota. All applicable ethical standards required by University of Minnesota IACUC was followed. All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}